BioSig (BSGM) 10-Q 28 Jul 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Jul. 28, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		14,706,368
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - Class of Stock [Domain] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 1,197,239	$ 239,781
Prepaid expenses	149,542	75,537
Total current assets	1,346,781	315,318
Property and equipment, net	16,650	13,020
Other assets:
Deposits	27,612	25,000
Total assets	1,391,043	353,338
Current liabilities:
Accounts payable and accrued expenses, including $13,905 and $40,293 to related parties as of June 30, 2015 and December 31, 2014 respectively	266,530	554,026
Stock based payable	132,684	226,305
Dividends payable	338,728	445,069
Warrant liability	4,056,531	0
Derivative liability	897,961	0
Total current liabilities	5,692,434	1,225,400
Series C 9% Convertible Preferred stock, 2,058 and 2,711 shares issued and outstanding, liquidation preference of $2,058,000 and $2,711,000, respectively	2,058,000	2,711,000
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	0	0
Common stock, $0.001 par value, authorized 50,000,000 shares, 14,499,535 and 11,179,266 issued and outstanding as of June 30, 2015 and December 31, 2014, respectively	14,500	11,179
Additional paid in capital	24,220,804	19,186,163
Accumulated deficit	(30,594,695)	(22,780,404)
Total stockholders' deficit	(6,359,391)	(3,583,062)
Total liabilities and stockholders' deficit	$ 1,391,043	$ 353,338

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parentheticals) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Accounts payable and accrued expenses, related parties (in Dollars)	$ 13,905	$ 40,293
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	14,499,535	11,179,266
Common stock, shares outstanding	14,499,535	11,179,266
Series C Preferred Stock [Member]
Preferred stock, Series C %	9.00%	9.00%
Preferred stock, shares issued	2,058	2,711
Preferred stock, shares outstanding	2,058	2,711
Preferred stock, liquidation preference (in Dollars)	$ 2,058,000	$ 2,711,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 328,498	$ 99,893	$ 630,577	$ 222,044
General and administrative	4,099,080	484,502	6,845,933	1,086,067
Depreciation	2,481	4,134	5,341	8,569
Total operating expenses	4,430,059	588,529	7,481,851	1,316,680
Loss from operations	(4,430,059)	(588,529)	(7,481,851)	(1,316,680)
Other income (expense):
Gain on change in fair value of derivatives	198,563	0	198,563	0
Interest income (expense)	(184)	(7,958)	(1,298)	(9,056)
Financing costs	(529,704)	(190,731)	(529,704)	(579,016)
Total other income (expense)	(331,325)	(198,689)	(332,439)	(588,072)
Loss before income taxes	(4,761,384)	(787,218)	(7,814,290)	(1,904,752)
Income taxes (benefit)	0	0	0	0
Net loss	(4,761,384)	(787,218)	(7,814,290)	(1,904,752)
Preferred stock dividend	(112,073)	(83,223)	(191,468)	(167,247)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (4,873,457)	$ (870,441)	$ (8,005,758)	$ (2,071,999)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.35)	$ (0.10)	$ (0.62)	$ (0.24)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	13,852,955	8,782,383	13,010,754	8,633,374

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]	Embedded Derivative Financial Instruments [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]	Options at $2.09 [Member]Common Stock [Member]	Options at $2.09 [Member]Additional Paid-in Capital [Member]	Options at $2.09 [Member]	Warrants at $3.67 [Member]Common Stock [Member]	Warrants at $3.67 [Member]Additional Paid-in Capital [Member]	Warrants at $3.67 [Member]	Warrants at $2.50 [Member]Common Stock [Member]	Warrants at $2.50 [Member]Additional Paid-in Capital [Member]	Warrants at $2.50 [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Warrants Exercised on Cashless Basis [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Warrant [Member]Warrants Exercised on Cashless Basis [Member]	Additional Paid-in Capital [Member]Warrant [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]Warrants Exercised on Cashless Basis [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Warrant [Member]Warrants Exercised on Cashless Basis [Member]	Warrant [Member]	Series C Preferred Stock [Member]	Total
Balance at Dec. 31, 2014																$ 11,179					$ 19,186,163	$ (22,780,404)				$ (3,583,062)
Balance (in Shares) at Dec. 31, 2014																11,179,266										11,179,266
Sale of common stock, net																$ 1,399					3,040,814					$ 3,042,213
Sale of common stock, net (in Shares)																1,398,760
Common stock issued upon conversion of preferred stock and accrued dividends					$ 10	$ 20,890	$ 20,900	$ 4	$ 14,977	$ 14,981	$ 4	$ 9,996	$ 10,000	$ 934	$ 100				$ 1,399,876	$ (100)					$ 1,400,810
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)					10,000			4,082			4,000			933,875	99,552
Reclassify fair value of derivative liability to (from) equity	$ 506,348	$ (1,242,590)	$ 506,348	$ (1,242,590)													$ 265,955	$ (4,097,444)					$ 265,955	$ (4,097,444)
Stock based compensation																					3,094,357					3,094,357
Preferred stock dividend																					(191,468)					(191,468)
Net loss																						(7,814,290)				(7,814,290)
Common stock issued for services																$ 870					2,213,030					2,213,900
Common stock issued for services (in Shares)																870,000
Balance at Jun. 30, 2015																$ 14,500					$ 24,220,804	$ (30,594,695)				$ (6,359,391)
Balance (in Shares) at Jun. 30, 2015																14,499,535										14,499,535

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (unaudited) (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2015
Warrants exercised (in Shares)	164,184
Common Stock [Member] | Warrants Exercised on Cashless Basis [Member]
Warrants exercised (in Shares)	156,102
Common Stock [Member] | Series C Preferred Stock [Member]
Conversion of preferred stock at	$ 1.50
Options at $2.09 [Member] | Common Stock [Member]
Common stock issued for exercise of options at	2.09
Warrants at $3.67 [Member] | Common Stock [Member]
Common stock issued for exercise of warrants at	3.67
Warrants at $2.50 [Member] | Common Stock [Member]
Common stock issued for exercise of warrants at	$ 2.50

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,814,290)	$ (1,904,752)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	5,341	8,569
Amortization of debt discount	585,324	579,016
Change in derivative liabilities	(198,563)	0
Equity based compensation	5,341,374	556,332
Changes in operating assets and liabilities:
Prepaid expenses	(107,122)	(21,806)
Accounts payable	(287,496)	(178,737)
Stock based payable	(93,621)	0
Deferred rent payable	0	(1,006)
Net cash used in operating activities	(2,569,053)	(962,384)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(8,971)	0
Payment of long term deposit	(2,612)	0
Net cash used in investing activity	(11,583)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	3,042,213	732,666
Proceeds from sale of Series C preferred stock	450,000	0
Proceeds from exercise of options	20,900	0
Proceeds from exercise of warrants	24,981	0
Net repayments of related party advances	0	(30,281)
Net cash provided by financing activities	3,538,094	702,385
Net increase (decrease) increase in cash and cash equivalents	957,458	(259,999)
Cash and cash equivalents, beginning of the period	239,781	302,187
Cash and cash equivalents, end of the period	1,197,239	42,188
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	1,298	9,056
Cash paid during the period for income taxes	0	0
Series C Preferred Stock [Member]
Non-cash investing and financing activities:
Common stock issued upon conversion of Series C preferred stock and accrued dividends	$ 1,400,810	$ 0

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Interim Financial Statements The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015. Basis of presentation The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at June 30, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable. The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Fair Value of Financial Instruments The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At June 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges. Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $328,498 and $630,577 for the three and six months ended June 30, 2015, respectively; and $99,893 and $222,044 for the three and six months ended June 30, 2014, respectively. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of June 30, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: June 30, 2015 June 30, 2014 Series C convertible preferred stock 1,372,000 1,854,019 Options to purchase common stock 7,330,190 2,990,977 Warrants to purchase common stock 7,772,277 4,502,459 Totals 16,474,467 9,347,455 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of June 30, 2015, the Company had 7,330,190 options outstanding to purchase shares of common stock, of which 4,801,017 were vested. As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested. Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. At June 30, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations. Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE 2 - PROPERTY AND EQUIPMENT

NOTE 2 - PROPERTY AND EQUIPMENT	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 2 – PROPERTY AND EQUIPMENT Property and equipment as of June 30, 2015 and December 31, 2014 is summarized as follows: June 30, 2015 December 31, 2014 Computer equipment $ 62,072 $ 54,900 Furniture and fixtures 9,602 7,803 Subtotal 71,674 62,703 Less accumulated depreciation (55,024 ) (49,683 ) Property and equipment, net $ 16,650 $ 13,020 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $2,481 and $5,341 for the three and six months ended June 30, 2015, respectively; and $4,134 and $8,569 for the three and six months ended June 30, 2014, respectively.

NOTE 3 - ACCOUNTS PAYABLE AND A

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at June 30, 2015 and December 31, 2014 consist of the following: June 30, 2015 December 31, 2014 Accrued accounting and legal $ 163,890 $ 190,767 Accrued reimbursements 13,905 26,792 Accrued consulting 19,471 16,334 Accrued research and development expenses 30,001 93,407 Accrued credit card obligations - 13,278 Accrued payroll - 62,068 Accrued liquidated damages - 55,620 Accrued office and other 23,318 29,093 Deferred rent 2,612 - Accrued settlement related to arbitration 13,333 66,667 $ 266,530 $ 554,026

NOTE 4 - SERIES C 9% CONVERTIBL

NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 4 – SERIES C 9% CONVERTIBLE PREFERRED STOCK On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock”). The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of Series C preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation. Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price of $1.50 (as reset). If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. During 2014, the resets provisions as described above resulted in the conversion price reset to $1.50. The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrant provides if, at any time while the warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share that is lower than the then conversion price (“base conversion price”), then the conversion price shall be reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. In addition, the warrants provides for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula. During 2014, the resets provisions as described above resulted in an additional 984,674 warrants issued with an exercise price reset to $1.50 all Series C warrants. In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value the conversion option ($1,303,671), relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C stockholders During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C 9% Convertible Preferred Stock. During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9% Convertible Preferred Stock for net proceeds of $1,814,910. At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. There was no established market for the Company’s common stock. As described in Note 6, March 31, 2015, the Company determined a market has been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities. At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%. During January 2015, the Company issued an aggregate of 42,334 shares of its common stock in exchange for 50 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. During March 2015, the Company issued an aggregate of 169,334 shares of its common stock in exchange for 200 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. In April 2015, the Company issued an aggregate of 152,401 shares of its common stock in exchange for 180 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. In May 2015, the Company issued an aggregate of 273,473 shares of its common stock in exchange for 323 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. In June 2015, the Company issued an aggregate of 296,333 shares of its common stock in exchange for 350 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. For the six months ended June 30, 2015 On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C 9% Convertible Preferred Stock for net proceeds of $450,000. In connection with the sale, the Company issued 374,641 warrants to purchase the Company’s common stock at a $1.50 per share for five years with certain reset provisions as described above. The Company determined the initial fair values of the embedded beneficial conversion feature of the Series C 9% Convertible Preferred Stock and the reset provisions of the related issued warrants $506,348 and $334,784, respectively, using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.25%, a dividend yield of 0%, and volatility of 140.00%. The determined fair values were recorded as liabilities and a charge to current period operations. Series C preferred stock issued and outstanding totaled 2,058 and 2,711 as of June 30, 2015 and December 31, 2014, respectively. As of June 30, 2015 and December 31, 2014, the Company has accrued $338,728 and $445,069 dividends payable on the Series C preferred stock. Registration Rights Agreement The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock. The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser. On June 23 2014, the Company became effective and met its required filing requirement. The Company did not meet the effectiveness obligation by November 22, 2013. As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At June 30, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

NOTE 5 - WARRANT AND DERIVATIVE

NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 5 – WARRANT AND DERIVATIVE LIABILITIES At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related warrants (see Note 5) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. . The Company valued the reset provisions of the Series C Convertible Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%. At June 30, 2015, the Company marked to market the fair value of the reset provisions of the Series C 9% Convertible Preferred Stock and warrants and determined fair values of $897,961 and $4,056,531, respectively. The Company recorded a gain from change in fair value of derivatives of $198,563 for the three and six months ended June 30, 2015. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 2.00 years, a risk free interest rate of 0.28, a dividend yield of 0%, and volatility of 140.00%.

NOTE 6 - STOCKHOLDER EQUITY

NOTE 6 - STOCKHOLDER EQUITY	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 – STOCKHOLDER EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of June 30, 2015 and December 31, 2014, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 , shares of Series C preferred stock. As of June 30, 2015 and December 31, 2014, there were no outstanding shares of Series A and Series B preferred stock. During January 2015, the Company issued an aggregate of 42,334 shares of its commons stock in exchange for 50 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends. During March 2015, the Company issued an aggregate of 169,334 shares of its commons stock in exchange for 200 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends. In April 2015, the Company issued an aggregate of 152,401 shares of its common stock in exchange for 180 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C 9% Convertible Preferred Stock for net proceeds of $450,000. In connection with the sale, the Company issued 374,641 warrants to purchase the Company’s common stock at a $1.50 per share for five years with certain reset provisions. In May 2015, the Company issued an aggregate of 273,473 shares of its common stock in exchange for 323 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. In June 2015, the Company issued an aggregate of 296,333 shares of its common stock in exchange for 350 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. Cumulatively, the Company exchanged 1,003 shares of the Company’s Series C 9% Convertible Stock and dividends with a recorded value of $1,400,810 for 933,875 shares of common stock. As of June 30, 2015 and December 31, 2014, the Company has 2,058 and 2,711 Series C 9% Convertible Preferred Stock issued and outstanding. Common stock The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of June 30, 2015 and December 31, 2014, the Company has 14,499,535 and 11,179,266 shares issued and outstanding, respectively. During the six months ended June 30, 2015, the Company issued an aggregate of 870,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $2,213,900 ($2.54 average per share). During the six months ended June 30, 2015, the Company issued 10,000 shares of common stock in exchange for options exercised at $2.09 per share. During the six months ended June 30, 2015, the Company issued an aggregate of 8,082 shares of common stock in exchange for warrants exercised at an average price of $3.09 per share. During the six months ended June 30, 2015, the Company issued 99,552 shares of common stock in exchange for 156,102 warrants exercised on a cashless basis. During the six months ended June 30, 2015, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 1,398,760 shares of common stock and warrants for aggregate proceeds of $3,042,213, net of $454,687 in expenses. In connection with the securities purchase agreements described above, the Company entered into a registration rights agreement whereas the Company is required to file a registration statement registering for resale the a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c) the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date. On May 20, 2015, the Company filed the required registration statement and on June 12, 2015, became effective meeting both requirements. The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser. Stock based payable The Company is obligated to issue shares of its common stock to board members and consultants for past and future services. The estimated liability as of March 31, 2015 and December 31, 2014 of $132,684 and $226,305 was determined based on services rendered for past services as of March 31, 2015 and December 31, 2014, respectively. As of June 30, 2015, the Company is obligated to issue an aggregate of 89,000 shares of its common stock. These shares were considered issued as of the date of obligation in determining the weighted average number of outstanding shares used in the basic loss per common share calculation.

NOTE 7 - OPTIONS, RESTRICTED ST

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 7 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 11,686,123,( as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan. During the six months ended June 30, 2015, the Company granted an aggregate of 1,350,000 options to officers, directors and key consultants. The following table presents information related to stock options at June 30, 2015: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 1,094,642 5.5 639,142 2.01-3.00 5,935,548 6.8 3,861,875 3.01-4.00 300,000 9.8 300,000 7,330,190 6.7 4,801,017 A summary of the stock option activity and related information for the 2012 Plan for the six months ended June 30, 2015 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2015 5,990,190 $ 2.25 6.7 3,267,692 Grants 1,350,000 2.75 10.0 - Exercised (10,000 ) 2.09 Canceled - Outstanding at June 30, 2015 7,330,190 $ 2.26 6.7 $ 860,542 Exercisable at June 30, 2015 4,801,017 $ 2.25 6.2 $ 601,896 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.30 as of June 30, 2015, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the six months ended June 30, 2015 was estimated using the Black-Scholes pricing model. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. During the six months ended June 30, 2015, the Company granted an aggregate of 1,350,000 options to purchase the Company stock in connection with the services rendered at the exercise prices from $2.00 to $3.99 per share for a term of seven years. Vesting is as follows: 450,000 50% immediately, 50% at first year anniversary 130,000 1/4 per quarter, over one year 65,000 50%, immediately, 50% performance contingent 300,000 1/12 per month beginning first month anniversary 405,000 Exercisable immediately 1,350,000 The fair value of the granted options for six months ended June 30, 2015 was determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: -0- % Volatility 129.54% to 130.30 % Risk free rate: 1.19% to 2.37 % Expected life: 7 to 10 Estimated fair value of the Company’s common stock $ 1.99 to $3.99 Estimated forfeiture rate 0 % On April 22, 2015, the Company issued 10,000 shares of common stock in exchange for options exercised at $2.09 per share. The fair value of all options vesting during the three and six months ended June 30, 2015 of $2,157,938 and $2,956,727, respectively, and during the three and six months ended June 30, 2014 of $212,495 and $556,332, respectively, was charged to current period operations. Unrecognized compensation expense of $2,674,190 at June 30, 2015 will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the six months ended June 30, 2015: Restricted shares issued as of January 1, 2015 - Granted 175,000 Total Restricted Shares Issued at June 30, 2015 175,000 Vested at December 31, 2014 (- ) Unvested restricted shares as of June 30, 2015 175,000 Stock based compensation expense related to restricted stock grants was $137,630 for the three and six months ended June 30, 2015; $-0- for the three and six months ended June 30, 2014. As of June 30, 2015, the stock-based compensation relating to restricted stock of $254,370 remains unamortized. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at June 30, 2015: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 3,940,057 February 2018 to September 2018 $ 1.84 35,076 January 2020 $ 2.02 30,755 January 2020 $ 2.50 1,599,600 July 2015 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 7,772,277 On January 23, 2015, the Company issued an aggregate of 428,400 and 321,300 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On February 10, 2015, the Company issued an aggregate of 337,000 and 252,750 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On February 27, 2015, the Company issued an aggregate of 223,000 and 167,250 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On March 31, 2015, the Company issued an aggregate of 410,360 and 307,770 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On April 15, 2015, the Company issued 99,552 shares of common stock in exchange for 156,102 warrants exercised on a cashless basis. On May 5, 2015, the Company issued 4,082 shares of common stock in exchange for 4,082 warrants exercised at $3.67 per share. On May 8, 2015, the Company issued 4,000 shares of common stock in exchange for 4,000 warrants exercised at $2.50 per share. On May 11, 2015, the Company issued an aggregate of 374,641 warrants to purchase the Company’s common stock at $1.50 per share expiring on May 11, 2020 in connection with the sale of the Company’s Series A 9% Convertible Preferred stock. A summary of the warrant activity for the six months ended June 30, 2015 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2015 5,113,990 $ 1.71 3.6 6,041,436 Grants 2,822,471 2.45 2.4 - Exercised (164,184 ) 1.58 Canceled Outstanding at June 30, 2015 7,772,277 $ 2.14 3.0 $ 4,058,045 Vested and expected to vest at June 30, 2015 7,772,277 $ 2.14 2.8 $ 4,058,045 Exercisable at June 30, 2015 7,772,277 $ 2.14 2.8 $ 4,058,045 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.30 as of June 30, 2015, which would have been received by the option holders had those option holders exercised their options as of that date.

NOTE 8 - FAIR VALUE MEASUREMENT

NOTE 8 - FAIR VALUE MEASUREMENT	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 8 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of June 30, 2015 or December 31, 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 6. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 6 are that of volatility and market price of the underlying common stock of the Company. As of June 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges. The derivative and warrant liability as of June 30, 2015, in the amount of $897,961 and $4,056,531 has a level 3 classification, respectively. The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of June 30, 2015: Warrant Liability Derivative Balance, December 31, 2014 $ - $ - Total (gains) losses Initial fair value of derivative at March 31, 2015, reclassified from equity - 1,242,590 Initial fair value of warrant liability at March 31, 2015, reclassified from equity 4,097,444 - Initial fair value of derivative at date of issuance of Series A 9% Convertible Preferred stock - 250,540 Initial fair value of warrant liability at the date of issuance 334,784 - Transfers out due to conversion of Series A 9% Convertible Preferred stock - (506,348 ) Transfers out due to exercise of warrants (265,955 ) - Mark to market to June 30, 2015 (109,742 ) (88,821 ) Balance, June 30, 2015 $ 4,056,531 $ 897,961 Gain on change in warrant and derivative liabilities for the six months ended June 30, 2015 $ 109,742 $ 88,821 Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 9 - SUBSEQUENT EVENTS

NOTE 9 - SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 9 – SUBSEQUENT EVENTS On July 7, 2015, the Company issued 37,500 shares of its common stock to consultants for services rendered. On July 17, 2015, the Company issued 169,333 shares of its common stock in exchange for 200 shares of its Series C 9% Convertible Preferred Stock and accrued dividends.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Interim Financial Statements The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements. Operating results for the three and six months ended June 30, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015. Basis of presentation The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at June 30, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable. The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At June 30, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $328,498 and $630,577 for the three and six months ended June 30, 2015, respectively; and $99,893 and $222,044 for the three and six months ended June 30, 2014, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of June 30, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: June 30, 2015 June 30, 2014 Series C convertible preferred stock 1,372,000 1,854,019 Options to purchase common stock 7,330,190 2,990,977 Warrants to purchase common stock 7,772,277 4,502,459 Totals 16,474,467 9,347,455
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. As of June 30, 2015, the Company had 7,330,190 options outstanding to purchase shares of common stock, of which 4,801,017 were vested. As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
Registration Rights Policy [Policy Text Block]	Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. At June 30, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE 1 - SUMMARY OF SIGNIFICA18

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: June 30, 2015 June 30, 2014 Series C convertible preferred stock 1,372,000 1,854,019 Options to purchase common stock 7,330,190 2,990,977 Warrants to purchase common stock 7,772,277 4,502,459 Totals 16,474,467 9,347,455

NOTE 2 - PROPERTY AND EQUIPME19

NOTE 2 - PROPERTY AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of June 30, 2015 and December 31, 2014 is summarized as follows: June 30, 2015 December 31, 2014 Computer equipment $ 62,072 $ 54,900 Furniture and fixtures 9,602 7,803 Subtotal 71,674 62,703 Less accumulated depreciation (55,024 ) (49,683 ) Property and equipment, net $ 16,650 $ 13,020

NOTE 3 - ACCOUNTS PAYABLE AND20

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at June 30, 2015 and December 31, 2014 consist of the following: June 30, 2015 December 31, 2014 Accrued accounting and legal $ 163,890 $ 190,767 Accrued reimbursements 13,905 26,792 Accrued consulting 19,471 16,334 Accrued research and development expenses 30,001 93,407 Accrued credit card obligations - 13,278 Accrued payroll - 62,068 Accrued liquidated damages - 55,620 Accrued office and other 23,318 29,093 Deferred rent 2,612 - Accrued settlement related to arbitration 13,333 66,667 $ 266,530 $ 554,026

NOTE 7 - OPTIONS, RESTRICTED 21

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at June 30, 2015: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 1,094,642 5.5 639,142 2.01-3.00 5,935,548 6.8 3,861,875 3.01-4.00 300,000 9.8 300,000 7,330,190 6.7 4,801,017
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the six months ended June 30, 2015 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2015 5,990,190 $ 2.25 6.7 3,267,692 Grants 1,350,000 2.75 10.0 - Exercised (10,000 ) 2.09 Canceled - Outstanding at June 30, 2015 7,330,190 $ 2.26 6.7 $ 860,542 Exercisable at June 30, 2015 4,801,017 $ 2.25 6.2 $ 601,896
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	During the six months ended June 30, 2015, the Company granted an aggregate of 1,350,000 options to purchase the Company stock in connection with the services rendered at the exercise prices from $2.00 to $3.99 per share for a term of seven years. Vesting is as follows: 450,000 50% immediately, 50% at first year anniversary 130,000 1/4 per quarter, over one year 65,000 50%, immediately, 50% performance contingent 300,000 1/12 per month beginning first month anniversary 405,000 Exercisable immediately 1,350,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the granted options for six months ended June 30, 2015 was determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: -0- % Volatility 129.54% to 130.30 % Risk free rate: 1.19% to 2.37 % Expected life: 7 to 10 Estimated fair value of the Company’s common stock $ 1.99 to $3.99 Estimated forfeiture rate 0 %
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the six months ended June 30, 2015: Restricted shares issued as of January 1, 2015 - Granted 175,000 Total Restricted Shares Issued at June 30, 2015 175,000 Vested at December 31, 2014 (- ) Unvested restricted shares as of June 30, 2015 175,000
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at June 30, 2015: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 3,940,057 February 2018 to September 2018 $ 1.84 35,076 January 2020 $ 2.02 30,755 January 2020 $ 2.50 1,599,600 July 2015 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 7,772,277
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the six months ended June 30, 2015 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2015 5,113,990 $ 1.71 3.6 6,041,436 Grants 2,822,471 2.45 2.4 - Exercised (164,184 ) 1.58 Canceled Outstanding at June 30, 2015 7,772,277 $ 2.14 3.0 $ 4,058,045 Vested and expected to vest at June 30, 2015 7,772,277 $ 2.14 2.8 $ 4,058,045 Exercisable at June 30, 2015 7,772,277 $ 2.14 2.8 $ 4,058,045

NOTE 8 - FAIR VALUE MEASUREME22

NOTE 8 - FAIR VALUE MEASUREMENT (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of June 30, 2015: Warrant Liability Derivative Balance, December 31, 2014 $ - $ - Total (gains) losses Initial fair value of derivative at March 31, 2015, reclassified from equity - 1,242,590 Initial fair value of warrant liability at March 31, 2015, reclassified from equity 4,097,444 - Initial fair value of derivative at date of issuance of Series A 9% Convertible Preferred stock - 250,540 Initial fair value of warrant liability at the date of issuance 334,784 - Transfers out due to conversion of Series A 9% Convertible Preferred stock - (506,348 ) Transfers out due to exercise of warrants (265,955 ) - Mark to market to June 30, 2015 (109,742 ) (88,821 ) Balance, June 30, 2015 $ 4,056,531 $ 897,961 Gain on change in warrant and derivative liabilities for the six months ended June 30, 2015 $ 109,742 $ 88,821

NOTE 1 - SUMMARY OF SIGNIFICA23

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Research and Development Expense	$ 328,498	$ 99,893	$ 630,577	$ 222,044
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	7,330,190		7,330,190		5,990,190
Registration Payment Arrangement, Accrual Carrying Value	$ 0		$ 0		$ 55,620
Employee Stock Option [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	7,330,190		7,330,190		5,990,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)	4,801,017		4,801,017		3,799,559

NOTE 1 - SUMMARY OF SIGNIFICA24

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	16,474,467	9,347,455
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,330,190	2,990,977
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,772,277	4,502,459
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,372,000	1,854,019

NOTE 2 - PROPERTY AND EQUIPME25

NOTE 2 - PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 2,481	$ 4,134	$ 5,341	$ 8,569
Minimum [Member]
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life			5 years

NOTE 2 - PROPERTY AND EQUIPME26

NOTE 2 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 71,674	$ 62,703
Less accumulated depreciation	(55,024)	(49,683)
Property and equipment, net	16,650	13,020
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	62,072	54,900
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 9,602	$ 7,803

NOTE 3 - ACCOUNTS PAYABLE AND27

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 163,890	$ 190,767
Accrued reimbursements	13,905	26,792
Accrued consulting	19,471	16,334
Accrued research and development expenses	30,001	93,407
Accrued credit card obligations	0	13,278
Accrued payroll	0	62,068
Accrued liquidated damages	0	55,620
Accrued office and other	23,318	29,093
Deferred rent	2,612	0
Accrued settlement related to arbitration	13,333	66,667
	$ 266,530	$ 554,026

NOTE 4 - SERIES C 9% CONVERTI28

NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	May. 11, 2015	Apr. 01, 2015	Feb. 06, 2013	Jan. 09, 2013	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jul. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted	374,641										2,822,471
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50
Warrants, Term of Warrants	5 years
Temporary Equity, Amortization Period															1 year
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)	$ 450,000										$ 450,000	$ 0
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	506,348				$ 897,961			$ 1,242,590		$ 1,242,590	897,961			$ 0
Derivative Liability, Current (in Dollars)	$ 334,784				4,056,531			$ 4,097,444		$ 4,097,444	4,056,531			0
Dividends Payable, Current (in Dollars)					338,728						$ 338,728			445,069
Registration Payment Arrangement, Term											The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)					$ 0						$ 0			$ 55,620
Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized				4,200	4,200						4,200			4,200
Preferred Stock, Dividend Rate, Percentage				9.00%							9.00%			9.00%
Temporary Equity, Par Value (in Dollars)				$ 1,000
Preferred Stock, Dividend Payment Terms				payable quarterly
Preferred Stock, Voting Rights				no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation.
Preferred Stock, Redemption Terms				(i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity.
Class of Warrant or Rights, Granted				1,330,627										984,674
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 2.61										$ 1.50
Warrants, Term of Warrants				5 years
Temporary Equity, Liquidation Preference (in Dollars)					$ 2,058,000						$ 2,058,000			$ 2,711,000	$ 2,781,000
Stock Issued During Period, Shares, New Issues	450												2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)													$ 1,814,910
Conversion of Stock, Shares Issued					296,333	273,473	152,401	169,334	42,334		933,875
Conversion of Stock, Shares Converted					350	323	180	200	50		1,003
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)	$ 450,000
Temporary Equity, Shares Issued					2,058						2,058			2,711
Temporary Equity, Shares Outstanding					2,058						2,058			2,711
Dividend Declared [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current (in Dollars)					$ 338,728						$ 338,728			$ 445,069
Options Held [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other (in Dollars)															1,303,671
Temporary Equity, Liquidation Preference (in Dollars)															1,303,671
Warrant [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Derivative Liability, Current (in Dollars)					$ 4,056,531						4,056,531
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)											$ (4,097,444)
Warrant [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)															1,064,739
Temporary Equity, Liquidation Preference (in Dollars)															1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference (in Dollars)															$ 412,590
Common Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Stock Issued During Period, Shares, New Issues											1,398,760
Common Stock [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Redemption Price Per Share (in Dollars per share)					$ 1.50						$ 1.50			$ 1.50
Embedded Derivative Financial Instruments [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Derivative Liability, Current (in Dollars)					$ 897,961						$ 897,961
Fair Value Assumptions, Expected Term	2 years	2 years									2 years
Fair Value Assumptions, Risk Free Interest Rate	0.25%										0.28%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%								0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate	140.00%									141.00%	140.00%
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)		$ 506,348									$ (1,242,590)
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)											$ 506,348
Bridge Loan [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			600
Minimum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term										2 years 284 days
Fair Value Assumptions, Risk Free Interest Rate		0.23%								0.56%
Fair Value Assumptions, Expected Volatility Rate		139.00%
Maximum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term										3 years 6 months
Fair Value Assumptions, Risk Free Interest Rate		0.27%								0.89%
Fair Value Assumptions, Expected Volatility Rate		140.00%

NOTE 5 - WARRANT AND DERIVATI29

NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	May. 11, 2015	Apr. 01, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	$ 506,348		$ 897,961	$ 1,242,590		$ 897,961		$ 0
Derivative Liability, Current (in Dollars)	$ 334,784		4,056,531	$ 4,097,444		4,056,531		$ 0
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			198,563		$ 0	198,563	$ 0
Embedded Derivative Financial Instruments [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Derivative Liability, Current (in Dollars)			897,961			$ 897,961
Fair Value Assumptions, Risk Free Interest Rate	0.25%					0.28%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%		0.00%		0.00%
Fair Value Assumptions, Expected Volatility Rate	140.00%			141.00%		140.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)						$ 88,821
Fair Value Assumptions, Expected Term	2 years	2 years				2 years
Warrant [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Derivative Liability, Current (in Dollars)			$ 4,056,531			$ 4,056,531
Derivative, Gain (Loss) on Derivative, Net (in Dollars)						$ 109,742
Minimum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.23%		0.56%
Fair Value Assumptions, Expected Volatility Rate		139.00%
Fair Value Assumptions, Expected Term				2 years 284 days
Maximum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.27%		0.89%
Fair Value Assumptions, Expected Volatility Rate		140.00%
Fair Value Assumptions, Expected Term				3 years 6 months

NOTE 6 - STOCKHOLDER EQUITY (De

NOTE 6 - STOCKHOLDER EQUITY (Details) - USD ($)	May. 11, 2015	Apr. 15, 2015	Jan. 09, 2013	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Jul. 31, 2013	Dec. 31, 2014
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized				1,000,000					1,000,000			1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)				$ 0.001					$ 0.001			$ 0.001
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)	$ 450,000								$ 450,000	$ 0
Class of Warrant or Rights, Granted	374,641								2,822,471
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50
Warrants, Term of Warrants	5 years
Common Stock, Shares Authorized				50,000,000					50,000,000			50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)				$ 0.001					$ 0.001			$ 0.001
Common Stock, Shares, Issued				14,499,535					14,499,535			11,179,266
Common Stock, Shares, Outstanding				14,499,535					14,499,535			11,179,266
Stock Issued During Period, Value, Issued for Services (in Dollars)									$ 2,213,900
Class of Warrant or Rights, Exercised									164,184
Proceeds from Issuance or Sale of Equity (in Dollars)									$ 3,042,213
Deferred Compensation Liability, Current (in Dollars)				$ 132,684					$ 132,684			$ 226,305
Common Stock, Shares Subscribed but Unissued				89,000					89,000
Private Placement [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues									1,398,760
Payments of Stock Issuance Costs (in Dollars)									$ 454,687
Securities Purchase Agreement									a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c) the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date. On May 20, 2015, the Company filed the required registration statement and on June 12, 2015, became effective meeting both requirements.The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser.
Warrants at $1.50 [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Rights, Granted	374,641
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50			$ 1.50					$ 1.50
Warrants, Term of Warrants	5 years
Warrants at $3.09 [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 3.09					$ 3.09
Stock Issued During Period, Shares, Other									8,082
Series A Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized				200					200			200
Preferred Stock, Shares Issued				0					0			0
Preferred Stock, Shares Outstanding				0					0			0
Series B Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized				600					600			600
Preferred Stock, Shares Issued				0					0			0
Preferred Stock, Shares Outstanding				0					0			0
Series C Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized				4,200					4,200			4,200
Temporary Equity, Shares Authorized			4,200	4,200					4,200			4,200
Conversion of Stock, Shares Issued				296,333	273,473	152,401	169,334	42,334	933,875
Conversion of Stock, Shares Converted				350	323	180	200	50	1,003
Stock Issued During Period, Shares, New Issues	450										2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)											$ 1,814,910
Class of Warrant or Rights, Granted			1,330,627									984,674
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 2.61									$ 1.50
Warrants, Term of Warrants			5 years
Conversion of Stock, Amount Issued (in Dollars)									$ 1,400,810	$ 0
Temporary Equity, Shares Issued				2,058					2,058			2,711
Temporary Equity, Shares Outstanding				2,058					2,058			2,711
Options at $2.09 [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Other									10,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)				$ 2.09					$ 2.09
Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services									870,000
Stock Issued During Period, Value, Issued for Services (in Dollars)									$ 2,213,900
Shares Issued, Price Per Share (in Dollars per share)				$ 2.54					$ 2.54
Warrants Exercised on Cashless Basis [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Other		99,552							99,552
Class of Warrant or Rights, Exercised		156,102							156,102

NOTE 7 - OPTIONS, RESTRICTED 31

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)

May. 11, 2015

May. 08, 2015

May. 05, 2015

Apr. 22, 2015

Apr. 15, 2015

Mar. 31, 2015

Feb. 27, 2015

Feb. 10, 2015

Jan. 23, 2015

Oct. 19, 2012

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,350,000

Share-based Compensation (in Dollars)

$ 5,341,374

$ 556,332

Class of Warrant or Rights, Granted

374,641

2,822,471

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.50

Class of Warrant or Rights, Exercised

164,184

Private Placement [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share Price (in Dollars per share)

$ 2.30

$ 2.30

Warrants at $2.50 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

2.50

2.50

Warrants at $2.50 [Member] | Private Placement [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

410,360

223,000

337,000

428,400

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.50

$ 2.50

$ 2.50

$ 2.50

Warrant, Expriation Date

Jul. 31, 2015

Jul. 31, 2015

Jul. 31, 2015

Warrants at $3.75 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 3.75

$ 3.75

Warrants at $3.75 [Member] | Private Placement [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

307,770

167,250

252,750

321,300

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 3.75

$ 3.75

$ 3.75

$ 3.75

Warrant, Expriation Date

Mar. 31, 2020

Mar. 31, 2020

Mar. 31, 2020

Mar. 31, 2020

Restricted Stock [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation (in Dollars)

$ 137,630

$ 0

$ 137,630

0

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options (in Dollars)

$ 254,370

$ 254,370

2012 Equity Incentive Plan [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

11,686,123

Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award

exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.

Common Stock, Capital Shares Reserved for Future Issuance

1,250,000

2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share Price (in Dollars per share)

$ 2.30

$ 2.30

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)

$ 2,157,938

$ 212,495

$ 2,956,727

$ 556,332

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

$ 2,674,190

$ 2,674,190

2012 Equity Incentive Plan [Member] | Directors and Key Consultants [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,350,000

Options at $2.09 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)

$ 2.09

Stock Issued During Period, Shares, Issued for Services

10,000

Warrants at $1.50 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Rights, Granted

374,641

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 1.50

Warrant, Expriation Date

May 11, 2020

Warrants at $1.50 [Member] | Warrants at $2.50 [Member] | Private Placement [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Warrant, Expriation Date

Jul. 31, 2015

Warrants Exercised on Cashless Basis [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Stock Issued During Period, Shares, Other

99,552

99,552

Class of Warrant or Rights, Exercised

156,102

156,102

Warrants at $3.67 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 3.67

Stock Issued During Period, Shares, Other

4,082

Class of Warrant or Rights, Exercised

4,082

Warrants at $2.50 [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 2.50

Stock Issued During Period, Shares, Other

4,000

Class of Warrant or Rights, Exercised

4,000

Maximum [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share Price (in Dollars per share)

$ 3.99

$ 3.99

Maximum [Member] | 2012 Equity Incentive Plan [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

10 years

Maximum [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)

3.99

3.99

Minimum [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share Price (in Dollars per share)

1.99

1.99

Minimum [Member] | 2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]

Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)

$ 2

$ 2

NOTE 7 - OPTIONS, RESTRICTED 32

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	7,330,190	5,990,190
Options Outstanding, Weighted Average Remaining Life	6 years 255 days	6 years 255 days
Options Exercisable, Number of Options	4,801,017
Options at $1.01-2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	1,094,642
Options Outstanding, Weighted Average Remaining Life	5 years 6 months
Options Exercisable, Number of Options	639,142
Options at $2.01-3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	5,935,548
Options Outstanding, Weighted Average Remaining Life	6 years 292 days
Options Exercisable, Number of Options	3,861,875
Options at $3.01-4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	9 years 292 days
Options Exercisable, Number of Options	300,000

NOTE 7 - OPTIONS, RESTRICTED 33

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares (in Shares)	7,330,190	5,990,190
Options Outstanding, Weighted-Average Exercise Price	$ 2.26	$ 2.25
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	6 years 255 days	6 years 255 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$ 860,542	$ 3,267,692
Exercisable at June 30, 2015 (in Shares)	4,801,017
Exercisable at June 30, 2015	$ 2.25
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	6 years 73 days
Exercisable at June 30, 2015 (in Dollars)	$ 601,896
Grants (in Shares)	1,350,000
Grants	$ 2.75
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm	10 years
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	$ 0
Exercised (in Shares)	(10,000)
Exercised	$ 2.09
Canceled (in Shares)	0
Canceled	$ 0

NOTE 7 - OPTIONS, RESTRICTED 34

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding - 6 months ended Jun. 30, 2015 - Options Granted for Services [Member] - shares	Total
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	1,350,000
Share-based Compensation Award, Tranche One [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	450,000
Vesting Description	50% immediately, 50% at first year anniversary
Share-based Compensation Award, Tranche Two [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	130,000
Vesting Description	1/4 per quarter, over one year
Share-based Compensation Award, Tranche Three [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	65,000
Vesting Description	50%, immediately, 50% performance contingent
Share-based Compensation Award, Tranche Four [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	300,000
Vesting Description	1/12 per month beginning first month anniversary
Share-based Compensation Award, Tranche Five [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Vesting	405,000
Vesting Description	Exercisable immediately

NOTE 7 - OPTIONS, RESTRICTED 35

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - Jun. 30, 2015 - $ / shares	Total
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield:	0.00%
Estimated forfeiture rate	0.00%
Minimum [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	129.54%
Risk free rate:	1.19%
Expected life:	7 years
Estimated fair value of the Company’s common stock (in Dollars per share)	$ 1.99
Maximum [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	130.30%
Risk free rate:	2.37%
Expected life:	10 years
Estimated fair value of the Company’s common stock (in Dollars per share)	$ 3.99

NOTE 7 - OPTIONS, RESTRICTED 36

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2015shares
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued as of January 1, 2015	0
Granted	175,000
Total Restricted Shares Issued at June 30, 2015	175,000
Vested at December 31, 2014	0
Unvested restricted shares as of June 30, 2015	175,000

NOTE 7 - OPTIONS, RESTRICTED 37

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	6 Months Ended
	Jun. 30, 2015	May. 11, 2015	Dec. 31, 2014
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)		$ 1.50
Number of Warrants Outstanding	7,772,277		5,113,990
Warrants at $0.001 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 0.001
Number of Warrants Outstanding	383,320
Expiration Date, Warrants	January 2,020
Warrants at $1.50 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.50	$ 1.50
Number of Warrants Outstanding	3,940,057
Expiration Date, Warrants	February 2018 to September 2018
Warrants at $1.84 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.84
Number of Warrants Outstanding	35,076
Expiration Date, Warrants	January 2,020
Warrants at $2.02 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.02
Number of Warrants Outstanding	30,755
Expiration Date, Warrants	January 2,020
Warrants at $2.50 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.50
Number of Warrants Outstanding	1,599,600
Expiration Date, Warrants	July 2,015
Warrants at $2.75 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.75
Number of Warrants Outstanding	228,720
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $3.67 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.67
Number of Warrants Outstanding	214,193
Expiration Date, Warrants	December 2018 to January 2019
Warrants at $3.75 [Member]
NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.75
Number of Warrants Outstanding	1,340,556
Expiration Date, Warrants	April 2019 to March 2020

NOTE 7 - OPTIONS, RESTRICTED 38

NOTE 7 - OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	May. 11, 2015	Jun. 30, 2015	Dec. 31, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares		7,772,277	5,113,990
Warrants Outstanding, Weighted-Average Exercise Price		$ 2.14	$ 1.71
WarrantsOutstandingWeightedAverageRemainingContractualTerm		3 years	3 years 219 days
Warrants Outstanding, Aggregate Intrinsic Value		$ 4,058,045	$ 6,041,436
Vested and expected to vest at June 30, 2015		7,772,277
Vested and expected to vest at June 30, 2015		$ 2.14
WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm		2 years 292 days
Vested and expected to vest at June 30, 2015		$ 4,058,045
Exercisable at June 30, 2015		7,772,277
Exercisable at June 30, 2015		$ 2.14
WarrantsExercisableWeightedAverageRemainingContractualTerm		2 years 292 days
Exercisable at June 30, 2015		$ 4,058,045
Grants	374,641	2,822,471
Grants		$ 2.45
Grants		2 years 146 days
Exercised		(164,184)
Exercised		$ 1.58
Canceled		0
Canceled		$ 0

NOTE 8 - FAIR VALUE MEASUREME39

NOTE 8 - FAIR VALUE MEASUREMENT (Details) - USD ($)	Jun. 30, 2015	May. 11, 2015	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 897,961	$ 506,348	$ 1,242,590	$ 0
Derivative Liability, Current	$ 4,056,531	$ 334,784	$ 4,097,444	$ 0

NOTE 8 - FAIR VALUE MEASUREME40

NOTE 8 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Total (gains) losses
Mark to market to June 30, 2015	$ (198,563)	$ 0	$ (198,563)	$ 0
Gain on change in warrant and derivative liabilities for the six months ended June 30, 2015	198,563	$ 0	198,563	$ 0
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014			0
Total (gains) losses
Initial fair value of derivative reclassified from equity			1,242,590
Initial fair value at the date of issuance			250,540
Transfers out			(506,348)
Mark to market to June 30, 2015			(88,821)
Balance, June 30, 2015	897,961		897,961
Gain on change in warrant and derivative liabilities for the six months ended June 30, 2015			88,821
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014			0
Total (gains) losses
Initial fair value of derivative reclassified from equity			4,097,444
Initial fair value at the date of issuance			334,784
Transfers out			(265,955)
Mark to market to June 30, 2015			(109,742)
Balance, June 30, 2015	$ 4,056,531		4,056,531
Gain on change in warrant and derivative liabilities for the six months ended June 30, 2015			$ 109,742

NOTE 9 - SUBSEQUENT EVENTS (Det

NOTE 9 - SUBSEQUENT EVENTS (Details) - shares	Jul. 17, 2015	Jul. 07, 2015	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Jun. 30, 2015
Series C Preferred Stock [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued			296,333	273,473	152,401	169,334	42,334	933,875
Conversion of Stock, Shares Converted			350	323	180	200	50	1,003
Subsequent Event [Member] | Series C Preferred Stock [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued	169,333
Conversion of Stock, Shares Converted	200
Subsequent Event [Member] | Stock Issued to Consultant [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		37,500

Uncategorized Items - bios-2015

Label	Element	Value
Net loss	us-gaap_NetIncomeLoss	$ (4,761,384)
Net loss	us-gaap_NetIncomeLoss	$ (787,218)